AMG National Trust Bank Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

AMG National Trust Bank purchased a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,688 shares of the company's stock, valued at approximately $271,000.

A number of other large investors have also recently modified their holdings of AZN. Brighton Jones LLC raised its holdings in shares of AstraZeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock worth $379,000 after purchasing an additional 2,789 shares during the last quarter. Proficio Capital Partners LLC raised its stake in AstraZeneca by 5.9% during the fourth quarter. Proficio Capital Partners LLC now owns 10,806 shares of the company's stock worth $708,000 after purchasing an additional 598 shares during the period. American Assets Inc. purchased a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $426,000. Xponance Inc. increased its stake in AstraZeneca by 6.9% during the 4th quarter. Xponance Inc. now owns 3,241 shares of the company's stock worth $212,000 after buying an additional 210 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its position in shares of AstraZeneca by 60.9% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 15,355 shares of the company's stock valued at $1,006,000 after purchasing an additional 5,809 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.

Wall Street Analyst Weigh In

AZN has been the subject of a number of recent research reports. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. BNP Paribas assumed coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $89.00.

AstraZeneca Stock Up 0.9%

Shares of NASDAQ:AZN traded up $0.62 during midday trading on Thursday, reaching $73.62. The company had a trading volume of 3,433,809 shares, compared to its average volume of 5,231,489. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The stock's fifty day moving average price is $70.96 and its 200-day moving average price is $71.02. The stock has a market capitalization of $228.32 billion, a P/E ratio of 29.56, a PEG ratio of 1.30 and a beta of 0.37. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the prior year, the company posted $2.06 earnings per share. The company's quarterly revenue was up 7.2% compared to the same quarter last year. Equities research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.